Previous 10 | Next 10 |
LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the appointment of Sara ...
LOS ALTOS, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief E...
2023-08-15 10:30:37 ET Unicycive Therapeutics press release ( NASDAQ: UNCY ): Q2 GAAP EPS of $0.29 beats by $0.57 . R&D expenses for the quarter ended June 30, 2023 were $2.3 million, compared to $1.9 million for the same period in 2022. As of June 30, 2023, ca...
Recent Data Publications Highlight the Benefits of Oxylanthanum Carbonate (OLC) to Improve Medication Adherence and Quality of Life for Patients with Chronic Kidney Disease Feedback from FDA Expected in Fall 2023 for OLC Program UNI-494 Phase 1 Trial Progressing as Planned with ...
ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies previously announced it would air interviews with 60 Degrees Pharmaceuticals, Inc. and Unicycive Therapeutics, Inc. (Nasdaq:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET). T...
ORLANDO, FL / ACCESSWIRE / July 21, 2023 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m. Eastern Time (ET). Bloomberg TV...
LOS ALTOS, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D.,...
LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that the peer-reviewed internatio...
2023-06-30 12:31:22 ET Gainers: Cyteir Therapeutics ( CYT ) +39% . Renalytix ( RNLX ) +39% . Rackspace Technology ( RXT ) +29% . Friedman Industries ( FRD ) +23% . Gracell Biotechnologies ( GRCL ) +23% . CytomX Therapeutics (...
2023-06-30 10:06:37 ET Gainers: CymaBay Therapeutics ( CBAY ) +36% . Cyteir Therapeutics ( CYT ) +34% . Renalytix ( RNLX ) +32% . CytomX Therapeutics ( CTMX ) +14% . Alvotech ( ALVO ) +13% . Losers: Unicycive Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
Unicycive Therapeutics Inc. Website:
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Pate...
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief E...
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a...